Session

Back to Programme Overview

Modern tools and new evidence in staging of urothelial carcinomas

Poster Session 29

  • Location:
    Room Madrid, North Hall (Level 1)
  • Chairs:
     M.J. Ribal, Barcelona (ES)
     D.J. Rosario, Sheffield (GB)
     T. Seisen, Paris (FR)
  • Aims and objectives of this session

    The proper diagnostic pathway, including demands for pathology and imaging, is an ongoing debate in bladder cancers.
    Non-muscle invasive papillary tumours confined to the mucosa and invading the lamina propria are classified as stage Ta and T1, respectively, according to the Tumour, Node, Metastasis (TNM) classification system. Flat, high-grade tumours that are confined to the mucosa are classified as CIS (Tis). New molecular biology techniques and clinical experience can pinpoint the highly malignant potential of selected CIS and T1 lesions. In muscle invasive bladder cancer both computed tomography (CT) and magnetic resonance imaging (MRI) may be used to detect T3b or higher disease. However, assessment of lymph node metastases with CT or MRI based on size and morphology has its limitations. This session aims to highlight new insights in the work-up of these tumors.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
380
Prognostic impact of a 12-gene progression score in non-muscle invasive bladder cancer: A prospective multicenter validation study

By: Dyrskjøt L.2, Reinert T.2, Algaba F.3, Christensen E.2, Nieboer D.4, Hermann G.5, Morgensen K.5, Marquez M.6, Segersten U.7, Hoyer S.8, Ulhøj B.8, Hartmann A.9, Stöhr R.9, Wach S.10, Nawroth R.11, Beukers W.20, Schwamborn K.12, Tulic C.13, Simic T.14, Junker K.15, Harving N.16, Petersen A.C.17, Jensen J.B.18, Keck B.10, Horstmann M.1, Maurer T.19, Steyerberg E.4, Zwarthoff E.20, Real F.6, Malats N.21, Malmström P-U.7, Ørntoft T.F.2

Institutes: 1Friedrich Schiller University of Jena, Dept. of Urology, Jena, Germany, 2Aarhus University Hospital, Dept. of Molecular Medicine, Aarhus, Denmark, 3University Autonoma De Barcelona, Section of Pathology, Fundacio Puigvert, Barcelona, Spain, 4Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands, 5Frederiksberg Hospital, Dept. of Urology, Frederiksberg, Denmark, 6Spanish National Cancer Research Centre, CNIO, Madrid, Spain, 7Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, 8University of Aarhus, Dept. of Pathology, Aarhus, Denmark, 9University Hospital of Erlangen, Dept. of Pathology, Erlangen-Nürnberg, Germany, 10University Hospital Erlangen, Dept. of Urology, Erlangen, Germany, 11Klinikum Rechts Der Isar, Technical University of Munich, Dept. of Urology, Munich, Germany, 12Klinikum Rechts Der Isar, Technical University of Munich, Dept. of Pathology, Munich, Germany, 13Faculty of Medicine, University of Belgrade, Dept. of Urology, Belgrade, Serbia, 14Faculty of Medicine, University of Belgrade, Institute of Medical and Clinical Biochemistry, Belgrade, Serbia, 15Saarland University, Dept. of Urology, Homburg, Germany, 16Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark, 17Aalborg University Hospital, Dept. of Pathology, Aalborg, Denmark, 18Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, 19Klinikum Rechts Der Isar, Technical University of Munick, Dept. of Urology, Munich, Germany, 20Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, 21Universitat Pompeu Fabra, Dept. of Experimental Science, Barcelona, Spain

381
11C-acetate PET-MRI in bladder cancer staging

By: Salminen A.1, Jambor I.2, Merisaari H.3, Ettala O.1, Virtanen J.2, Koskinen I.4, Veskimäe E.5, Sairanen J.4, Minn H.6, Kemppainen J.7, Boström P.1

Institutes: 1Turku University Hospital, Dept. of Urology, Turku, Finland, 2Turku University Hospital, Dept. of Diagnostic Radiology, Turku, Finland, 3University of Turku, Dept. of Information Technology, Turku, Finland, 4Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, 5Tampere University Hospital, Dept. of Urology, Tampere, Finland, 6Turku University Hospital, Dept. of Clinical Oncology, Turku, Finland, 7Turku University Hospital, Dept. of Clinical Physiology, Nuclear Medicine and PET Imaging, Turku, Finland

382
Metric sub-stage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer

By: Fransen Van De Putte E.1, Van Der Kwast T.2, Bertz S.3, Denzinger S.4, Manach Q.5, Compérat E.6, Boormans J.7, Jewett M.8, Stoehr R.3, Zlotta A.9, Hendricksen K.1, Rouprêt M.5, Otto W.4, Burger M.4, Hartmann A.3, Van Rhijn B.1

Institutes: 1Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, 2University of Toronto, Princess Margaret Cancer Center, Dept. of Pathology, Toronto, Canada, 3University of Erlangen, Dept. of Pathology, Erlangen, Germany, 4University of Regensburg, Caritas Krankenhaus St. Joseph, Dept. of Urology, Regensburg, Germany, 5Hôpital Universitaire Pitié-Salpétrière, Dept. of Urology, Paris, France, 6Hôpital Universitaire Pitié-Salpétrière, Dept. of Pathology, Paris, France, 7Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands, 8University of Toronto, Princess Margaret Cancer Center, Dept. of Surgery (Urology), Toronto, Canada, 9Univerisity of Toronto, Mount Sinai Hospital, Dept. of Surgery (Urology), Toronto, Canada

383
A panel of micro-RNA signature as a tool for predicting survival of patients with urothelial carcinoma of the bladder

By: Inamoto T.1, Takahara K.2, Ibuki N.2, Takai T.2, Uchimoto T.2, Saito K.2, Tanda N.2, Yoshikawa Y.2, Minami K.2, Hirano H.2, Nomi H.2, Azuma H.2

Institutes: 1Osaka Medical College, Osaka, Japan, 2Osaka Medical College, Dept. of Urology, Osaka, Japan

384
Using the EORTC risk tables & the CUETO scoring model for predicting recurrence and progression in non-muscle invasive bladder cancer: A local single centre experience

By: Lee S.L., Lim S.K., Ng K.K., Ng F.C.

Institutes: Changi General Hospital, Dept. of Urology, Singapore, Singapore

385
Using liquid biopsy to assess the genomic landscape of metastatic urothelial carcinoma

By: Todenhöfer T.1, Vandekerkhove G.2, Struss W.2, Annala M.2, Beja K.2, Eigl B.2, Mischinger J.1, Stenzl A.1, Black P.2, Wyatt A.2

Institutes: 1Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, 2University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada

386
Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and morphological imaging in recurrent urothelial carcinomas: A retrospective, multi-center study

By: Zattoni F.1, Ficarra V.2, Briganti A.3, Colicchia M.4, Fanti S.5, Karnes R.J.4, Incerti E.6, Lowe V.7, Moschini M.3, Panareo S.8, Picchio M.6, Rambaldi I.9, Schiavina R.10, Zattoni F.12, Evangelista L.11

Institutes: 1University of Padua, Dept. of Surgery, Oncology and Gastroenterology, Padua, Italy, 2University of Udine, Dept. of Experimental and Clinical Medical Sciences, Udine, Italy, 3Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, 4Mayo Clinic, Dept. of Urology, Rochester, United States of America, 5Sant’Orsola-Malpighi Hospital, Dept. of Nuclear Medicine, Bologna, Italy, 6IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, 7Mayo Clinic, Dept. of Nuclear Medicine, Rochester, United States of America, 8University Hospital of Ferrara, Dept. of Diagnostic Imaging E Laboratory Medicine, Ferrara, Italy, 9University Hospital of Ferrara, Nuclear Medicine Unit, Diagnostic Imaging E Laboratory Medicine Department, Ferrara, Italy, 10Sant’Orsola-Malpighi Hospital, Dept. of Urology, Bologna, Italy, 11Veneto Institute of Oncology IOV – IRCCS, Nuclear Medicine and Molecular Imaging Unit, Padua, Italy, 12University of Padua, Dept. of Surgery, Oncology, and Gastroenterology, Padua, Italy

387
Prognostic impact of immunohistochemical classification of bladder cancer according to luminal (Uroplakin III) and basal (Cytokeratin 5/6) markers

By: Hayashi T.1, Sentani K.2, Kakumoto S.1, Oo H.Z.3, Sakamoto N.2, Mutaguchi K.4, Kobatake K.1, Goto K.1, Inoue S.1, Teishima J.1, Yasui W.2, Black P.C.3, Matsubara A.1

Institutes: 1Hiroshima University, Dept. of Urology, Hiroshima, Japan, 2Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan, 3Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada, 4Nakatsu Daiichi Hospital, Dept. of Urology, Nakatsu, Japan

388
Validation of preoperative thrombocytosis as adverse prognostic factor in advanced bladder cancer (BCA) after radical cystectomy (RC)

By: Foerster B.1, Moschini M.1, Abufaraj M.1, Soria F.1, Lotan Y.2, Karakiewicz P.3, Briganti A.4, Babjuk M.5, Rink M.6, Kluth L.6, John H.7, Shariat S.1

Institutes: 1Medical University of Vienna, Dept. of Urology, Vienna, Austria, 2University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, 3University of Montreal, Dept. of Urology, Montreal, Canada, 4Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, 5Faculty Hospital Motol, Second Faculty of Medicine, Charles University In Praha, Dept. of Urology, Prague, Czech Republic, 6University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 7Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland

389
Preoperative hemoglobin to platelet ratio as a predictor of survival after radical cystectomy due to bladder cancer, synergic effect of anemia and thrombocytosis

By: La Croce G.1, Moschini M.1, Dell’Oglio P.1, Nini A.1, Bandini M.1, Capogrosso P.1, Ventimiglia E.1, Sanchez-Salas R.2, Salonia A.1, Briganti A.1, Montorsi F.1, Gallina A.1, Colombo R.1

Institutes: 1IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 2L’Institut Mutualiste Montsouris, Dept. of Urology, Paris, France

390
Tumor regression grading after neoadjuvant chemotherapy in bladder cancer: Validation in an independent cohort

By: Seiler R.1, Oo H.Z.2, Todenhöfer T.2, Fazli L.2, Daugaard M.2, Black P.2

Institutes: 1Universitätsspital Bern, Universitätsklinik für Urologie, Bern, Switzerland, 2University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada

391
Potential utility of apparent diffusion coefficient (ADC) value as a biomarker to predict the difference between T1G3 non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC)

By: Masaaki F.1, Sakamoto S.2, Sekita N.1, Sato H.1, Kono H.1, Nishikawa R.1, Takeuchi N.2, Suzuki H.3, Mikami K.4, Ichikawa T.2

Institutes: 1Chibaken Saiseikai Narashino Hospital, Dept. of Urology, Narashino, Japan, 2Chiba University, Dept. of Urology, Chiba, Japan, 3Toho University Medical Center, Sakura Hospital, Dept. of Urology, Sakura, Japan, 4Chibaken Saiseikai Narashino Hospital, Dept. of Urology, Sakura, Japan

392
The effects of 18F-FDG PET/CT on the management and prognosis of patients with bladder cancer (BCa) and upper urinary tract urothelial carcinoma (UTUC)

By: Zattoni F.1, Briganti A.2, Colicchia M.3, Castellucci P.4, Ficarra V.5, Karnes R.J.3, Fallanca F.6, Lowe V.7, Massari F.8, Gallina A.2, Bartolomei M.9, Picchio M.6, Ippolito C.10, Schiavina R.11, Zattoni F.1, Evangelista L.12

Institutes: 1University of Padua, Dept. of Surgery, Oncology, and Gastroenterology, Padua, Italy, 2URI, IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, 3Mayo Clinic, Dept. of Urology, Rochester, United States of America, 4Sant’Orsola-Malpighi Hospital, Dept. of Nuclear Medicine, Bologna, Italy, 5University of Udine, Dept. of Experimental and Clinical Medical Sciences, Udine, Italy, 6IRCCS Ospedale San Raffaele, Milan, Italy, Dept. of Nuclear Medicine, Milan, Italy, 7Mayo Clinic, Dept. of Nuclear Medicine, Rochester, United States of America, 8S. Orsola-Malpighi Hospital, Dept. of Medical Oncology, Bologna, Italy, 9University Hospital of Ferrara, Dept. of Diagnostic Imaging E Laboratory Medicine, Ferrara, Italy, 10University- Hospital of Ferrara, Dept. of Surgery, Ferrara, Italy, 11Sant’Orsola-Malpighi Hospital, Dept. of Urology, Bologna, Italy, 12Veneto Institute of Oncology IOV – IRCCS, Nuclear Medicine and Molecular Imaging Unit, Padua, Italy

Summary
 D.J. Rosario, Sheffield (GB)